INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
基本信息
- 批准号:2389919
- 负责人:
- 金额:$ 18.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-04-01 至 2000-03-31
- 项目状态:已结题
- 来源:
- 关键词:acute phase protein adipocytes alcoholic liver cirrhosis antifibrinolytic agents antiinflammatory agents colchicine collagen collagenase cytokine cytokine receptors disease /disorder model extracellular matrix fibrogenesis fibrosis gene expression inflammation interleukin 1 interleukin 6 laboratory rat liver cells liver pharmacology northern blottings tissue /cell culture tissue inhibitor of metalloproteinases tumor necrosis factor alpha
项目摘要
Liver cirrhosis is among the leading causes of death worldwide.
Approximately 50% of the deaths attributable to liver cirrhosis recognize
alcohol as the main ethiologic agent. Currently, there is no accepted
treatment for this disease. The available treatment is directed primarily
to complications of cirrhosis and not to inhibit the inflammatory or
fibrogenic mechanisms. Close to 3 billion dollars were spent for the
treatment of patients with liver cirrhosis in 1992. Therefore, the
development of a treatment for this disease will relieve the suffering of
hundreds of thousands and will save the USA government millions of
dollars. Patients with alcoholic hepatitis have several of the
manifestations of the acute-phase response (APR). They also have elevated
levels of IL-1, IL-6 and TNF-alpha. These same cytokines are involved in
cell injury and production of extracellular matrix by liver fat-storing
cells. We have obtained evidence to suggest that IL-6 is a fibrogenic
cytokine that induces the expression of alpha1(I) procollagen mRNA. In
addition, TNF-alpha is a cytokine that mediates cell injury. Therefore,
drugs that inhibit synthesis and/or secretion of cytokines or that prevent
their biological activity could ameliorate liver cirrhosis. Colchicine is
an orphan drug that has been used successfully for the treatment of
cirrhosis. However, its mechanism of action remains to be elucidated.
Recent evidence suggests that colchicine inhibits the release of cytokines
and growth factors, prevents the cytotoxic effect of TNF-alpha and
enhances the release of TNF-alpha soluble receptors. The long-term
objectives of this proposal are to evaluate the contribution of the APR,
and of IL-1, IL-6 and TNF-alpha in the development of liver cirrhosis and
explore the anti-inflammatory and anti-fibrogenic potential of colchicine.
Our specific aims are: (1) To investigate the mechanisms by which the APR
contributes to liver fibrosis and to determine the molecular mechanisms by
which cytokines modulate type I collagen gene expression in fat-storing
cells. The mechanisms by which colchicine prevents the APR will be
explored. (2) To study the role of IL-1, IL-6 and TNF-alpha in inducing
excess matrix deposition in a rat model of alcoholic cirrhosis, and
evaluate the effectiveness of colchicine as a therapeutic agent for
alcoholic liver cirrhosis. If we could better understand the mechanisms
by which colchicine prevents liver fibrosis and improves liver function we
could test the anti-inflammatory and anti-fibrogenic potential of many
compounds, including a large number of colchicine derivatives currently
available.
肝硬化是世界范围内死亡的主要原因之一。
大约50%的死于肝硬化的人认识到,
酒精是主要的精神因素。 目前,没有接受
治疗这种疾病。 现有的治疗方法主要针对
肝硬化的并发症,而不是抑制炎症或
纤维化机制 近30亿美元用于
1992年治疗肝硬化患者。 因此
开发治疗这种疾病的方法将减轻
数十万人,并将为美国政府节省数百万美元
美元. 酒精性肝炎患者有几种
急性期反应(APR)。 他们还提高了
IL-1、IL-6和TNF-α水平。 这些细胞因子参与了
肝贮脂对细胞损伤及细胞外基质的产生
细胞 我们已经获得的证据表明IL-6是一种纤维化因子,
诱导α 1(I)前胶原mRNA表达的细胞因子。 在
此外,TNF-α是介导细胞损伤的细胞因子。 因此,我们认为,
抑制细胞因子的合成和/或分泌或预防
其生物活性可改善肝硬化。 秋水仙碱是
一种孤儿药,已成功用于治疗
肝硬化 然而,其作用机制仍有待阐明。
最近的证据表明,秋水仙碱抑制细胞因子的释放
和生长因子,防止TNF-α的细胞毒性作用,
增强TNF-α可溶性受体的释放。 长期
该提案的目的是评估APR的贡献,
以及IL-1、IL-6和TNF-α在肝硬化发展中的作用,
探讨秋水仙碱的抗炎和抗纤维化潜力。
我们的具体目标是:(1)研究APR的机制,
有助于肝纤维化,并确定分子机制,
哪些细胞因子调节I型胶原基因在脂肪储存中的表达
细胞 秋水仙碱预防APR的机制将是
探讨了 (2)研究IL-1、IL-6和TNF-α在诱导人肝癌细胞凋亡中的作用,
在酒精性肝硬化大鼠模型中过量基质沉积,和
评估秋水仙碱作为治疗药物的有效性,
酒精性肝硬化。 如果我们能更好地理解
秋水仙碱通过预防肝纤维化和改善肝功能,
可以测试抗炎和抗纤维化的潜力,
化合物,包括目前大量的秋水仙碱衍生物,
available.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARCOS ROJKIND其他文献
MARCOS ROJKIND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARCOS ROJKIND', 18)}}的其他基金
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6371374 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6128654 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6629598 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6495544 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6731971 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
6509228 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
2047189 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
INTERLEUKIN 6 ROLE IN ALCOHOLIC LIVER CIRRHOSIS
白细胞介素 6 在酒精性肝硬化中的作用
- 批准号:
7052752 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
Role of Acetaldehyde on PDGF-BB-induced HSC Migration
乙醛对 PDGF-BB 诱导的 HSC 迁移的作用
- 批准号:
7050518 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
Role of Acetaldehyde on PDGF-BB-induced HSC Migration and Proliferation.
乙醛对 PDGF-BB 诱导的 HSC 迁移和增殖的作用。
- 批准号:
7228134 - 财政年份:1995
- 资助金额:
$ 18.91万 - 项目类别:
相似国自然基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
- 批准号:81970721
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
- 批准号:
23K16058 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
- 批准号:
23K10969 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
- 批准号:
10751284 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
- 批准号:
23H03065 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
- 批准号:
23K05107 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
- 批准号:
23K19518 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
- 批准号:
23K18303 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
- 批准号:
10655793 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
- 批准号:
23K05594 - 财政年份:2023
- 资助金额:
$ 18.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Characterizing breast cancer invasion and proliferation when co-aggregated with adipocytes in multicellular spheroids created with a custom bioreactor to augment cell-cell connectivity.
当与多细胞球体中的脂肪细胞共聚集时,表征乳腺癌的侵袭和增殖,该多细胞球体是用定制生物反应器创建的,以增强细胞间的连接。
- 批准号:
10334113 - 财政年份:2022
- 资助金额:
$ 18.91万 - 项目类别: